128 related articles for article (PubMed ID: 38360293)
1. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
[TBL] [Abstract][Full Text] [Related]
2. Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist.
Pickford P; Lucey M; Rujan RM; McGlone ER; Bitsi S; Ashford FB; Corrêa IR; Hodson DJ; Tomas A; Deganutti G; Reynolds CA; Owen BM; Tan TM; Minnion J; Jones B; Bloom SR
Mol Metab; 2021 Sep; 51():101242. PubMed ID: 33933675
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
Marzook A; Chen S; Pickford P; Lucey M; Wang Y; Corrêa IR; Broichhagen J; Hodson DJ; Salem V; Rutter GA; Tan TM; Bloom SR; Tomas A; Jones B
Biochem Pharmacol; 2021 Aug; 190():114656. PubMed ID: 34129856
[TBL] [Abstract][Full Text] [Related]
4. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-like peptide-1 receptor internalisation controls spatiotemporal signalling mediated by biased agonists.
Fletcher MM; Halls ML; Zhao P; Clydesdale L; Christopoulos A; Sexton PM; Wootten D
Biochem Pharmacol; 2018 Oct; 156():406-419. PubMed ID: 30195733
[TBL] [Abstract][Full Text] [Related]
6. Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s).
Jorgensen R; Kubale V; Vrecl M; Schwartz TW; Elling CE
J Pharmacol Exp Ther; 2007 Jul; 322(1):148-54. PubMed ID: 17395766
[TBL] [Abstract][Full Text] [Related]
7. Abolishing β-arrestin recruitment is necessary for the full metabolic benefits of G protein-biased glucagon-like peptide-1 receptor agonists.
Hinds CE; Peace E; Chen S; Davies I; El Eid L; Tomas A; Tan T; Minnion J; Jones B; Bloom SR
Diabetes Obes Metab; 2024 Jan; 26(1):65-77. PubMed ID: 37795639
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors.
Darbalaei S; Yuliantie E; Dai A; Chang R; Zhao P; Yang D; Wang MW; Sexton PM; Wootten D
Biochem Pharmacol; 2020 Oct; 180():114150. PubMed ID: 32682761
[TBL] [Abstract][Full Text] [Related]
9. Divergent acute versus prolonged pharmacological GLP-1R responses in adult β cell-specific β-arrestin 2 knockout mice.
Bitsi S; El Eid L; Manchanda Y; Oqua AI; Mohamed N; Hansen B; Suba K; Rutter GA; Salem V; Jones B; Tomas A
Sci Adv; 2023 May; 9(18):eadf7737. PubMed ID: 37134170
[TBL] [Abstract][Full Text] [Related]
10. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
[TBL] [Abstract][Full Text] [Related]
11. β-Arrestin-Biased Agonists of the GLP-1 Receptor from β-Amino Acid Residue Incorporation into GLP-1 Analogues.
Hager MV; Johnson LM; Wootten D; Sexton PM; Gellman SH
J Am Chem Soc; 2016 Nov; 138(45):14970-14979. PubMed ID: 27813409
[TBL] [Abstract][Full Text] [Related]
12. Two distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism.
Lei S; Clydesdale L; Dai A; Cai X; Feng Y; Yang D; Liang YL; Koole C; Zhao P; Coudrat T; Christopoulos A; Wang MW; Wootten D; Sexton PM
J Biol Chem; 2018 Jun; 293(24):9370-9387. PubMed ID: 29717000
[TBL] [Abstract][Full Text] [Related]
13. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
14. The glucagon-like peptide-2 receptor C terminus modulates beta-arrestin-2 association but is dispensable for ligand-induced desensitization, endocytosis, and G-protein-dependent effector activation.
Estall JL; Koehler JA; Yusta B; Drucker DJ
J Biol Chem; 2005 Jun; 280(23):22124-34. PubMed ID: 15817468
[TBL] [Abstract][Full Text] [Related]
15. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
16. Residues within the transmembrane domain of the glucagon-like peptide-1 receptor involved in ligand binding and receptor activation: modelling the ligand-bound receptor.
Coopman K; Wallis R; Robb G; Brown AJ; Wilkinson GF; Timms D; Willars GB
Mol Endocrinol; 2011 Oct; 25(10):1804-18. PubMed ID: 21868452
[TBL] [Abstract][Full Text] [Related]
17. Allosteric ligands of the glucagon-like peptide 1 receptor (GLP-1R) differentially modulate endogenous and exogenous peptide responses in a pathway-selective manner: implications for drug screening.
Koole C; Wootten D; Simms J; Valant C; Sridhar R; Woodman OL; Miller LJ; Summers RJ; Christopoulos A; Sexton PM
Mol Pharmacol; 2010 Sep; 78(3):456-65. PubMed ID: 20547734
[TBL] [Abstract][Full Text] [Related]
18. Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.
Deganutti G; Liang YL; Zhang X; Khoshouei M; Clydesdale L; Belousoff MJ; Venugopal H; Truong TT; Glukhova A; Keller AN; Gregory KJ; Leach K; Christopoulos A; Danev R; Reynolds CA; Zhao P; Sexton PM; Wootten D
Nat Commun; 2022 Jan; 13(1):92. PubMed ID: 35013280
[TBL] [Abstract][Full Text] [Related]
19. Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1.
Hager MV; Clydesdale L; Gellman SH; Sexton PM; Wootten D
Biochem Pharmacol; 2017 Jul; 136():99-108. PubMed ID: 28363772
[TBL] [Abstract][Full Text] [Related]
20. Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in mice.
Gabe MBN; von Voss L; Hunt JE; Gadgaard S; Gasbjerg LS; Holst JJ; Kissow H; Hartmann B; Rosenkilde MM
Br J Pharmacol; 2023 Jul; 180(13):1674-1689. PubMed ID: 36683195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
